(MedPage Today) — An individualized dosing regimen of the inhaled psychedelic mebufotenin (GH001) led to significant improvements in depression symptoms in patients with treatment-resistant depression, a randomized placebo-controlled trial showed…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
